Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...